Intellia announced a new tool for gene editing. Academics said they rewrote history
David Liu, the Harvard biochemist, was sitting in a meeting last week when his phone started buzzing repeatedly.
Unbeknownst to him, minutes prior the CRISPR company Intellia had finished unveiling their approach to base editing at a Cold Spring Harbor Lab conference. First pioneered by Liu and his lab in 2016, the method allows you to change individual DNA bases without breaking the double helix, an advance that could prove critical for treating a long list of cancers and genetic diseases.